A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes

Inclusion criteria

• Male and female subjects, aged 18 to 60 years, who are English or Spanish speakers.
• BMI 25 to 34.9 kg/m2
• Subject has type 2 diabetes with HgbA1c < 8.0%
• Subject's glucose is controlled with either diet alone or oral agents that do not cause hypoglycemia (e.g. Metformin, DPP-4 inhibitors, Thiazolidinediones, Alpha-Glucosidase Inhibitors and GLP-1 agonists).
• Subject is motivated to increase their activity and make other lifestyle changes.
• Subject has:

• A compatible Apple mobile device with the iOS 7 operating system installed:

• iPhone 4 or newer
• iPad 2 or newer
• iPad Mini
• iPod touch 5th gen (2012 model) or newer
• 500MB of free space on the iPhone, iPad, or iPod touch
• A valid mobile phone number to receive daily updates via SMS text messaging
• An active iTunes account/password to install study-related software ("apps")
• Access to Wi-Fi or a mobile data plan to send study data
• Female subject is surgically sterile, post-menopausal or agrees to use an acceptable method of birth control as defined in section 2.7.
• Subject agrees to not use any new vitamin and/or mineral supplement until after study completion.
• Subject agrees to not take any dietary or herbal supplements or products until after study completion. Seven-day washout period prior to study inclusion allowed.
• Subject is willing and able to comply with the protocol including:

• Attending 3 visits, approximately 2 hours each
• Wearing and inputting required information into the Fitbit Flex activity tracker
• Receiving alerts from the Medidata Patient Cloud
• Working on making nutrition and exercise changes over the 8-week study period
• Using and updating his/her iPhone, iPad, iPad Mini or iTouch as per study requirements (e.g. downloading the iOS7 operating system, downloading the Medidata Patient Cloud and Fitbit Flex apps, and receiving daily text messages).
• Subject is able to understand and sign the informed consent to participate in the study.

Exclusion criteria

• Subject has any of the following medical conditions:

• active heart disease
• uncontrolled high blood pressure (≥ 140/90 mmHg)
• renal or hepatic impairment/disease
• Type I diabetes
• bipolar disorder
• active psychiatric disease
• Parkinson's disease
• unstable thyroid disease
• immune disorder (such as HIV/AIDS)
• any medical condition deemed exclusionary by the Principal Investigator (PI)
• Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within five years prior to screening.
• Subject is taking oral agents that can cause hypoglycemia (e.g. sulfonylureas, meglitinides and insulin).
• Subject is taking or has taken in the past 28 days any supplement or medication (prescription or over the counter) for weight loss (see section 2.6.2); 28-day washout required for study inclusion.
• Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).
• Subject is currently taking any medication deemed exclusionary by PI.
• Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ 2 times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.
• Subject has a clinically relevant abnormality as defined by the PI or interpreting physician with respect to the electrocardiogram (ECG).
• Subject has a QTc interval > 450 msec for males and > 470 msec for females.
• Subject has a history of drug or alcohol abuse in the past 12 months.
• Subject has begun/stopped smoking ≤ 6 months ago OR has plans to begin/quit smoking.
• Subject has experienced a weight loss or gain greater than 4.5 kg (approximately 10 lbs) in the past 3 months.
• Subject is pregnant, lactating, or planning to become pregnant during the study period.
• Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
• Subject has taken an investigational product within 30 days of study enrollment (visit 2).